aTyr Pharma, Inc.
ATYR
$0.53
-$0.03-5.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -19.15% | -19.15% | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -19.15% | -19.15% | -100.00% | -100.00% |
| Cost of Revenue | 5.49% | 10.75% | 12.13% | 7.58% | 14.14% |
| Gross Profit | -5.13% | -10.88% | -12.26% | -8.85% | -15.61% |
| SG&A Expenses | 24.80% | 27.73% | 29.10% | 24.52% | 8.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.59% | 14.19% | 15.45% | 10.99% | 12.96% |
| Operating Income | -9.30% | -14.30% | -15.57% | -12.03% | -14.09% |
| Income Before Tax | -10.44% | -15.78% | -17.73% | -15.11% | -17.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.44% | -15.78% | -17.73% | -15.11% | -17.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 25.00% | 600.00% | 600.00% | 600.00% | 33.33% |
| Net Income | -10.43% | -15.77% | -17.72% | -15.10% | -17.58% |
| EBIT | -9.30% | -14.30% | -15.57% | -12.03% | -14.09% |
| EBITDA | -9.46% | -14.52% | -15.79% | -12.20% | -14.25% |
| EPS Basic | 8.93% | 8.32% | 10.90% | 11.89% | 10.72% |
| Normalized Basic EPS | 8.95% | 8.36% | 10.91% | 11.90% | 10.72% |
| EPS Diluted | 8.93% | 8.32% | 10.90% | 11.89% | 10.72% |
| Normalized Diluted EPS | 8.95% | 8.36% | 10.91% | 11.90% | 10.72% |
| Average Basic Shares Outstanding | 20.81% | 25.22% | 30.38% | 31.16% | 33.11% |
| Average Diluted Shares Outstanding | 20.81% | 25.22% | 30.38% | 31.16% | 33.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |